OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS | Delayed Deutsche Boerse AG 11:34:56 2024-06-05 EDT | ||
| 20.76 EUR | -1.89% |
|
| Current month | -7.88% | ||
| 1 month | -24.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 20.76 | -1.89% |
| 24-06-04 | 21.16 | -3.42% |
| 24-06-03 | 21.91 | -4.61% |
| 24-05-31 | 22.97 | -5.63% |
| 24-05-30 | 24.34 | +0.33% |
Delayed Quote Deutsche Boerse AG
Last update June 05, 2024 at 11:34 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SW2EQR |
| ISIN | DE000SW2EQR9 |
| Date issued | 2023-08-17 |
| Strike | 705.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 32.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 34.18 € |
|---|---|
| Lowest since issue | 20.76 € |
| Spread | 0.05 € |
| Spread % | 0.24% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
475
USD
Average target price
463.5
USD
Spread / Average Target
-2.41%
- Stock Market
- Certificates
- Certificat
